CYTOMEDIX JOINS THE ACUTE LONG TERM HOSPITAL ASSOCIATION (ALTHA) AS AN ALLIED MEMBER Company to Exhibit at ALTHA’s Spring Meeting May 14-16, 2008 Rockville, MD, May 14, 2008 – Cytomedix, Inc. (AMEX: GTF), today announced that it has joined the Acute Long Term Hospital Association (ALTHA) as a Silver member and will be exhibiting during the upcoming conference in Baltimore, MD, May 14-16. ALTHA is the Washington based trade association of Long Term Acute Care Hospitals (LTACs) and represents over 300 of the LTAC hospitals nationwide. ALTHA plays an important role protecting patient access to quality long term hospital care. “Given the importance of LTACs to our strategy, ALTHA represents a significant opportunity to create and reinforce relationships with the clinicians and executives who manage this provider segment,” said David Hotchkiss, VP Sales and Marketing for Cytomedix, Inc. “We offer a significant value proposition to the LTAC providers by allowing them to manage chronic wound conditions in their patients cost effectively.” Long Term Acute Care Hospitals are often referred to as specialty hospitals, or a hospital-inhospital. They are designed for patients whose condition is too acute for a nursing home or home care. Often patients will be admitted to an LTAC until their condition is improved enough for less costly extended care. Many LTAC patients also have challenging chronic ulcers that can delay or prevent discharge. “We look forward to participating with ALTHA and to a continuing relationship with the membership,” said Kshitij Mohan, Ph.D., Chairman and Chief Executive Officer of Cytomedix, Inc. “Our value proposition involves our AutoloGel™ System, and provides for demonstrating this unique wound management system utilizing platelet rich plasma (PRP) gel for use in a wide variety of exuding wounds, including diabetic ulcers, leg ulcers and pressure ulcers and other surgically or mechanically debrided wounds.” ABOUT CYTOMEDIX Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for use on wounds and other applications. The current offering is the AutoloGel™ System, a process that utilizes an autologous platelet gel composed of multiple growth factors, other platelet releasates, and fibrin matrix. Additional information regarding Cytomedix is available at: http://www.cytomedix.com. SAFE HARBOR STATEMENT Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the success of new sales initiatives, governmental regulation, acceptance by the LTAC medical community, and the competition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.